

## AMENDMENTS TO THE SPECIFICATION

### IN THE SPECIFICATION

**On page 7, line 1, please replace the original paragraph with the following amended paragraph:**

-- Mention may also be made of the following peptide conjugates:

|           |   |
|-----------|---|
| Peptide R | H-Gly-His-Lys-OH,   |
| Peptide S | Lipoyl-Lys-Gly-His-Lys-NH <sub>2</sub> , <u>(SEQ ID NO: 12)</u> |
| Peptide V | Ac-Lys-Gly-His-Lys-NH <sub>2</sub> . <u>(SEQ ID NO: 12)</u> --  |

**On page 8, line 9, please replace the original paragraph with the following amended paragraph:**

-- Other peptides or peptide conjugates can also be combined with the peptides or peptide conjugates whose use is the subject of the present invention. They correspond to the formulae

W-Lys-Asp-Val-Z (I) (SEQ ID Nos. 15-16)

or the peptide conjugate thereof corresponding to formula (II)

A-W-Lys-Asp-Val-Z (II) (SEQ ID Nos. 17-18)

in which A has the same definition as that given above,

and W represents

Glu-Gln-Arg, Arg-Lys, Arg-Lys-Asp, Arg or a bond,

when Z represents

Tyr-Val-Gln-Leu-Tyr-NH<sub>2</sub> (SEQ ID NO: 19), Leu-DOPA, DOPA-NH<sub>2</sub> or  
HomoPhe-NH<sub>2</sub>,

or else W represents

Gly-Gln-Gln or Glu-Gln,

when Z represents

Tyr-Val-Gln-Leu-Tyr-NH<sub>2</sub>(SEQ ID NO: 19), Leu-DOPA, Val-Tyr-OH, Val-Tyr-NH<sub>2</sub>, Tyr-NH<sub>2</sub>, Tyr-OH, DOPA-NH<sub>2</sub> or HomoPhe-NH<sub>2</sub>, in the form of enantiomers or of diastereoisomers, and also the mixtures thereof, including racemic mixtures, and the complexes with zinc which can be formed with these peptides or peptide conjugates. --

**On page 11, line 2, please replace the original paragraph with the following amended paragraph:**

-- Example 1: Lotion comprising the peptide conjugate Ac-Lys-Gly-His-Lys-NH<sub>2</sub> (SEQ ID NO: 12) --

**On page 11, line 10, please replace the original paragraph with the following amended paragraph:**

-- Example 2: Lotion comprising the peptide conjugate Lipoyl-Lys-Gly-His-Lys-NH<sub>2</sub> (SEQ ID NO: 12)--